Upgrade to SI Premium - Free Trial

Novan (NOVN)

0.09 0.00 (0.00%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (11/13/23 *Est.)

Latest Headlines

New England Journal of Medicine publishes Phase III data showing Xolair® (omalizumab) significantly reduced allergic reactions across multiple foods in people with food allergies February 25, 2024 2:00 PM - PR NewsWire Sandoz receives Health Canada approval for Jubbonti®, first and only denosumab biosimilar for treatment of osteoporosis February 20, 2024 8:10 AM - Globe NewsWire FDA approves Xolair® (omalizumab) as first and only medicine for children and adults with one or more food allergies February 16, 2024 11:21 AM - PR NewsWire Form S-8 POS NOVARTIS AG February 15, 2024 4:16 PM - SEC Filing Form SC 13G/A NOVARTIS AG Filed by: BlackRock Inc. February 2, 2024 2:19 PM - SEC Filing Form 6-K NOVARTIS AG For: Dec 31 January 31, 2024 7:45 AM - SEC Filing Form 6-K NOVARTIS AG For: Dec 31 January 31, 2024 7:44 AM - SEC Filing Form IRANNOTICE NOVARTIS AG January 31, 2024 7:42 AM - SEC Filing Form 20-F NOVARTIS AG For: Dec 31 January 31, 2024 7:40 AM - SEC Filing Form 6-K NOVARTIS AG For: Jan 08 January 8, 2024 6:14 AM - SEC Filing Novartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand therapy manufacturing facility in Indianapolis January 5, 2024 9:23 AM - Globe NewsWire Full Article List